FluBlok, a next generation influenza vaccine manufactured in insect cells

Biologicals

Volumn 37, Issue 3, 2009, Pages 182-189

  Cox, Manon M J ^a   Hollister, Jason R ^a  

^a Protein Sciences Corp   (United States)

Author keywords

Baculovirus; Cell substrate; Hemagglutinin; Influenza vaccine; Insect cells

Indexed keywords

DOUBLE STRANDED DNA; EGG PROTEIN; FLUBLOK; HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO; RECOMBINANT TRIVALENT HEMAGGLUTININ VACCINE; SINGLE STRANDED DNA; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG APPROVAL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; HUMAN; INFLUENZA; INJECTION SITE PAIN; INSECT CELL; INSECT CELL CULTURE; INSECT CELL EXPRESSF; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANIMALS; INFLUENZA VACCINES; INSECTS; VACCINES, SYNTHETIC;

HEXAPODA; ORTHOMYXOVIRIDAE; TIPULA IRIDESCENT VIRUS;

EID: 67349134258     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.02.014     Document Type: Article

References (40)

1. Cox M.M., and Anderson D.K. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir Viruses 1 1 (2007) 35-40
2. Treanor J.J., Schiff G.M., Couch R.B., Cate T.R., Brady R.C., Hay C.M., et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 193 9 (2006) 1223-1228
3. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297 14 (2007) 1577-1582
4. Keitel W.A., Cate T.R., Atmar R.L., Turner C.S., Nino D., Dukes C.M., et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 3 5 (1996) 507-510
5. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 32 10 (1994) 2468-2473
6. Wood J.M. Standardization of inactivated influenza vaccine (1998), Blackwell Science, London p. 333-45
7. Bridges C.B., Fukuda K., Uyeki T.M., Cox N.J., and Singleton J.A. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 51 RR-3 (2002) 1-31
8. Huber V.C., and McCullers J.A. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 10 1 (2008) 75-85
9. Holtz K.M., Anderson D.K., and Cox M.M. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J 2 (2003) 25-32
10. Wang K., Holtz K.M., Anderson K., Chubet R., Mahmoud W., and Cox M.M. Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine 24 12 (2006) 2176-2185
11. Kida H., Webster R.G., and Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 76 2 (1983) 91-99
12. Yoden S., Kida H., Kuwabara M., Yanagawa R., and Webster R.G. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res 4 3 (1986) 251-261
13. Rohwer R.G. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE). Dev Biol Stand 88 (1996) 247-256
14. Nims R.W. Detection of adventitious viruses in biologicals - a rare occurrence. Dev Biol (Basel) 123 (2006) 153-164 discussion 83-97
15. Chen D., Nims R., Dusing S., Miller P., Luo W., Quertinmont M., et al. Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization - a case study. Biologicals (2008)
16. In: Miller L.K., and Ball L.A. (Eds). The insect viruses (1998), Plenum Pub. Corp.
17. Kuno G., and Chang G.J. Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends. Clin Microbiol Rev 18 4 (2005) 608-637
18. Zhang P.F., Klutch M., Muller J., and Marcus-Sekura C.J. Susceptibility of the Sf9 insect cell line to infection with adventitious viruses. Biologicals 22 3 (1994) 205-213
19. Knezevic I., Stacey G., and Petricciani J. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007. Biologicals 36 3 (2008) 203-211
20. Vaughn J.L., Goodwin R.H., Tompkins G.J., and McCawley P. The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). In Vitro 13 4 (1977) 213-217
21. McPherson C.E. Development of a novel recombinant influenza vaccine in insect cells. Biologicals (2008)
22. Green J.A., and Baron S. 5-Iododeoxyuridine potentiation of the replication in vitro of several unrelated RNA and DNA viruses. Science 190 4219 (1975) 1099-1101
23. Carreno G., and Esparza J. Induction of Venezuelan equine encephalitis (Mucambo) virus by iododeoxyuridine in chronically infected 'cured' cultured mosquito cells. Intervirology 8 4 (1977) 193-203
24. Patch C.T., Chattopadhyay S.K., Hauser J., and Levine A.S. Regulation of viral transcription in cells infected with iododeoxyuridine-substituted simian virus 40 as a model for the activation by iododeoxyuridine of latent viral genomes. Cancer Res 41 6 (1981) 2421-2427
25. Khan A.S., and Sears J.F. Pert analysis of endogenous retroviruses induced from K-BALB mouse cells treated with 5-iododeoxyuridine: a potential strategy for detection of inducible retroviruses from vaccine cell substrates. Dev Biol (Basel) 106 (2001) 387-392 discussion 92-3
26. Khan A.S., Muller J., and Sears J.F. Early detection of endogenous retroviruses in chemically induced mouse cells. Virus Res 79 1-2 (2001) 39-45
27. Huhtala A., Linko P., and Mutharasan R. Protein response of insect cells to bioreactor environmental stresses. J Biotechnol 118 3 (2005) 278-289
28. Rose T.M. CODEHOP-mediated PCR - a powerful technique for the identification and characterization of viral genomes. Virol J 2 (2005) 20
29. Jarrett R.F., Johnson D., Wilson K.S., and Gallagher A. Molecular methods for virus discovery. Dev Biol (Basel) 123 (2006) 77-88 discussion 119-32
30. Baines J.E., McGovern R.M., Persing D., and Gostout B.S. Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomas. J Virol Methods 123 1 (2005) 81-87
31. Rose T.M., Schultz E.R., Henikoff J.G., Pietrokovski S., McCallum C.M., and Henikoff S. Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences. Nucleic Acids Res 26 7 (1998) 1628-1635
32. Terzian C., Pelisson A., and Bucheton A. Evolution and phylogeny of insect endogenous retroviruses. BMC Evol Biol 1 (2001) 3
33. Li T.C., Scotti P.D., Miyamura T., and Takeda N. Latent infection of a new alphanodavirus in an insect cell line. J Virol 81 20 (2007) 10890-10896
34. NCT00395174: Comparison of the immunogenicity, safety and reactogenicity of FluBlØk™, to a licensed vaccine in elderly adults (2007), National Institutes of Health, Bethesda, MD, USA
35. NCT00539981: Immunogenicity, safety, reactogenicity, efficacy, effectiveness and lot consistency of FluBlok (2007), National Institutes of Health, Bethesda, MD, USA
36. NCT00539864: Safety and reactogenicity of FluBlok and comparison of immunogenicity, efficacy and effectiveness against TIV (2007), National Institutes of Health, Bethesda, MD, USA
37. Cox M.M., Patriarca P.A., and Treanor J.J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses 2 6 (2008) 201-209
38. Safdar A., Rodriguez M.A., Fayad L.E., Rodriguez G.H., Pro B., Wang M., et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194 10 (2006) 1394-1397
39. Renfrey S., and Watts A. Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12 8 (1994) 747-752
40. Hehme N, Engelmann H, Raderecht C, Porstmann T. Comparative laboratory results of different commercial influenza vaccines. Option for the control of influenza V, Okinawa, Japan; 2003. Poster W07P-41.